Amicus Cash Beginning of Year vs Cash End of Year Analysis
FOLD Stock | USD 10.54 0.17 1.59% |
Trend analysis of Amicus Therapeutics balance sheet accounts such as Other Assets of 41.8 M or Common Stock Shares Outstanding of 309.9 M provides information on Amicus Therapeutics' total assets, liabilities, and equity, which is the actual value of Amicus Therapeutics to its prevalent stockholders. By breaking down trends over time using Amicus Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Amicus |
About Amicus Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Amicus Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Amicus Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Amicus Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Amicus currently owns. An asset can also be divided into two categories, current and non-current.
Amicus Therapeutics Balance Sheet Chart
Amicus Therapeutics Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Amicus Therapeutics uses and utilizes its capital. It also shows what exactly a company owns and owes.
At present, Amicus Therapeutics' Common Stock Shares Outstanding is projected to increase significantly based on the last few years of reporting. The current year's Other Stockholder Equity is expected to grow to about 3 B, whereas Retained Earnings are projected to grow to (2.5 B). Add Fundamental
Total Assets
Total assets refers to the total amount of Amicus Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Amicus Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Most indicators from Amicus Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Amicus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.At present, Amicus Therapeutics' Issuance Of Capital Stock is projected to decrease significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 4.6 B, whereas Sales General And Administrative To Revenue is forecasted to decline to 1.19.
2023 | 2024 (projected) | Extraordinary Items | 90K | 85.5K | Reconciled Depreciation | 7.0M | 6.3M |
Amicus Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Amicus Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Amicus Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 850.2M | 886.5M | 905.1M | 724.2M | 777.9M | 451.1M | |
Total Stockholder Equity | 476.4M | 286.4M | 307.4M | 123.0M | 160.2M | 168.7M | |
Retained Earnings | (1.8B) | (2.0B) | (2.3B) | (2.5B) | (2.7B) | (2.5B) | |
Other Assets | 51.3M | 65.4M | 47.4M | 42.2M | 48.6M | 41.8M | |
Common Stock Shares Outstanding | 240.4M | 258.9M | 271.4M | 289.1M | 295.2M | 309.9M | |
Liabilities And Stockholders Equity | 850.2M | 886.5M | 905.1M | 724.2M | 777.9M | 473.3M | |
Other Stockholder Equity | 2.2B | 2.3B | 2.6B | 2.7B | 2.8B | 3.0B | |
Total Liab | 373.8M | 600.1M | 597.8M | 601.1M | 617.7M | 648.6M | |
Other Current Liab | 1.3M | 104.2M | 117.1M | 110.1M | 131.8M | 138.4M | |
Total Current Liabilities | 128.8M | 129.7M | 146.0M | 139.0M | 167.7M | 176.1M | |
Accounts Payable | 120.4M | 17.1M | 21.5M | 15.4M | 15.1M | 21.1M | |
Cash | 142.8M | 163.2M | 245.2M | 148.8M | 247.0M | 259.3M | |
Short Term Investments | 309.9M | 320.0M | 237.3M | 144.8M | 39.2M | 37.2M | |
Other Current Assets | 20.0M | 29.7M | 34.8M | 40.2M | 49.5M | 52.0M | |
Common Stock | 2.6M | 2.7M | 2.8M | 2.8M | 2.9M | 3.1M | |
Property Plant Equipment | 47.7M | 43.9M | 42.5M | 30.8M | 35.4M | 37.2M | |
Short Long Term Debt Total | 210.2M | 441.7M | 440.1M | 452.1M | 445.1M | 467.3M | |
Other Liab | 41.9M | 35.6M | 19.1M | 18.5M | 21.3M | 20.2M | |
Property Plant And Equipment Net | 81.0M | 67.2M | 63.1M | 60.3M | 58.0M | 60.9M | |
Net Debt | 67.4M | 278.5M | 194.9M | 303.3M | 198.1M | 208.0M | |
Non Current Assets Total | 330.1M | 307.1M | 308.3M | 300.4M | 294.8M | 204.5M | |
Non Currrent Assets Other | 28.3M | 19.1M | 24.4M | 10.0M | 15.5M | 16.2M | |
Long Term Debt | 149.5M | 389.3M | 389.4M | 392.0M | 387.9M | 407.3M | |
Cash And Short Term Investments | 452.7M | 483.3M | 482.5M | 293.6M | 286.2M | 251.3M | |
Common Stock Total Equity | 2.6M | 2.7M | 2.8M | 2.8M | 3.2M | 3.4M | |
Non Current Liabilities Total | 245.0M | 470.5M | 451.8M | 462.1M | 450.0M | 243.4M | |
Property Plant And Equipment Gross | 81.0M | 67.2M | 83.0M | 82.6M | 83.4M | 87.6M | |
Total Current Assets | 520.1M | 579.5M | 596.8M | 423.8M | 483.1M | 293.7M | |
Accumulated Other Comprehensive Income | 2.8M | 8.2M | 5.0M | (12.1M) | 5.3M | 5.6M | |
Net Tangible Assets | 255.6M | 65.6M | 86.6M | (97.8M) | (112.4M) | (106.8M) | |
Net Receivables | 33.3M | 46.9M | 52.7M | 66.2M | 87.6M | 92.0M | |
Retained Earnings Total Equity | (1.8B) | (2.0B) | (2.3B) | (2.5B) | (2.3B) | (2.2B) | |
Capital Surpluse | 2.2B | 2.3B | 2.6B | 2.7B | 3.1B | 1.7B | |
Inventory | 14.0M | 19.6M | 26.8M | 23.8M | 59.7M | 62.7M | |
Deferred Long Term Liab | 14.0M | 12.3M | 10.8M | 9.6M | 8.6M | 8.2M | |
Non Current Liabilities Other | 81.5M | 68.9M | 51.6M | 60.5M | 13.3M | 12.6M |
Amicus Therapeutics Investors Sentiment
The influence of Amicus Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Amicus. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Amicus Therapeutics' public news can be used to forecast risks associated with an investment in Amicus. The trend in average sentiment can be used to explain how an investor holding Amicus can time the market purely based on public headlines and social activities around Amicus Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Amicus Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Amicus Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Amicus Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Amicus Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Amicus Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Amicus Therapeutics' short interest history, or implied volatility extrapolated from Amicus Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Amicus Stock analysis
When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Amicus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.51) | Revenue Per Share 1.353 | Quarterly Revenue Growth 0.306 | Return On Assets (0.06) | Return On Equity (1.07) |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.